The first oncology biosimilar—filgrastim-sndz (Zarxio)—was approved in the United States in March 2015, but this category of drugs is still fairly misunderstood, according to Jim M. Koeller, MS, Professor, College of Pharmacy, University of Texas at Austin.
Physicians need to advocate for molecular profiling, according to Howard “Skip” Burris III, MD.

Results 1 - 2 of 2